DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT06934655

Not yet recruitingPhase 3

Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth

Asset

Semaglutide

GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

150

estimated

Study population

Bariatric Surgery, Obesity / overweight

Key I/E criterion

—

Primary endpoint

•Percent Body Mass Index

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06934655
Org study IDAPP-IP

Timeline

Milestones

Study first posted2025-04-18actual
Last update posted2026-03-17actual
Study start2026-06-01estimated
Primary completion2030-11-01estimated
Study completion2033-11-01estimated

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Bariatric SurgeryObesity / overweight

Eligibility

Who can enroll

Minimum age12 Years
Maximum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•ages 12 to 18 years
•Tanner stage 3 or higher
•severe obesity (defined as a BMI greater than 35 kg/m2 or BMI ≥140% of the 95th percentile)
•currently undergoing primary surgical weight loss through the pediatric bariatric surgery pathway at Children's Hospital Los Angeles
•be willing to have blood collected before and after surgical procedure at defined points
•be willing to have clinical data entered into a prospective database; 8) presence of a consenting caregiver
•be taking semaglutide 2.4 mg weekly as part of their routine medical care prior to surgery as part of their obesity treatment program, apart from any planned surgical procedure.

Exclusion criteria

•have a previous diagnosis of type 1 diabetes
•taking any medications known to influence body composition or prevent weight loss or promote weight gain (e.g. prednisone)
•have been diagnosed with syndromes or diseases that may influence the postoperative course (e.g., Cushing syndrome, Down syndrome, Prader Willi Syndrome)
•have significant comorbid medical conditions necessitating frequent hospitalization that may require interruption of medications and/or that would make early re-initiation of semaglutide unsafe due to the other medical comorbidities
•refuse to comply with eligibility criteria.

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
1
Glycemic / diabetes
1
Other clinical outcomes
1

Weight & body composition

1 endpoint
Primary/protocol endpoint

Percent Body Mass Index

Time frame:From enrollment to the end of the end of the study at 24 months

descriptive, improvement

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint

Modified percent time in range

Time frame:From enrollment to the end of the study period at 24 months

CGM time-in-range

percent change from baseline, improvement

Other clinical outcomes

1 endpoint
Other/protocol endpoint

Eating in the absence of hunger

Time frame:Month 24 compared to baseline

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.